

IN THE SPECIFICATION

Please delete the paragraph inserted by the Preliminary Amendment of August 30, 2001 at page 1, line 4, and insert the following paragraph:

B1 ~~A~~ This application is a division of U.S. application Serial No. 08/945,289, filed October 17, 1997, in issue, which is a continuation-in-part of U.S. application Serial No. 08/432,483, filed May 1, 1995, now U.S. Patent 6,410,022. ~~4~~

A version of the amended paragraph with markings on a separate sheet pursuant to 37 C.F.R. § 1.121(b) is provided as Exhibit A.

RECEIVED

FEB 10 2003

IN THE CLAIMS

Please amend the claims to appear as written below pursuant to 37 C.F.R. § ~~1.121(c)(1)(i)~~ **TECH CENTER 1600/2900** 1.121(c)(1)(i). A version of the amended claims with markings on a separate sheet pursuant to 37 C.F.R. § 1.121(c)(1)(ii) is provided as Exhibit B, and a complete set of pending claims, as amended herein, is provided pursuant to 37 C.F.R. § 1.121(c)(3) as Exhibit C.

Amended Claims

28. (amended) A method for treating or preventing atherosclerosis in a human or animal comprising administering to said human or animal an antigenic vaccine peptide comprising a universal helper T cell epitope portion linked to a B cell epitope portion, wherein said B cell epitope portion comprises a B cell epitope of CETP.

B 2 29. (amended) The method according to claim 28, wherein said helper T cell epitope portion comprises a helper T cell epitope derived from an antigenic peptide selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis vaccine, Bacille Calmette-Guerin (BCG), polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, purified protein derivative of tuberculin, keyhole limpet hemocyanin, hsp70, and combinations thereof.

37. (amended) The method according to claim 28, wherein said B cell epitope portion of the antigenic vaccine peptide comprises 6 to 26 consecutive amino acids of the carboxyl terminal 26 amino acids of human cholesteryl ester transfer protein (SEQ ID NO:1).